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ticagrelor or prasugrel 
 
UFH or LMWH/fondaparinux 
or bivalirudin 
+ 
In hospital 12 months DAPT, dual antiplatelet therapy; 
LMWH, low molecular weight heparin; 
UFH, unfractionated heparin 











DAPT post ACS 
Rationale for 12 months of treatment duration 
Total death / AMI at 12 months 
Event rate 
Revascularization (+) 5.2% 



















Morais J  et al  
Unpublished data 
Single centre (n=965) 
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CURE PLATO 
TRITON 
DAPT post ACS 
Rationale for 12 months of treatment duration 

? 
? ? ? ? ? ? 
Stent oriented strategy 

Time duration can be shorten ?  
Capodanno D, Circulation. 2013;128:2785-2798 













TIMI Major Bleeding 
  Odds Ration 
 M-H Random 95% CI 
 
1.15 |0.85, 1.54] 
 
 
0.95 [0.66, 1.36] 
 
 
0.88 [0.43, 1.81] 
 
 
1.51 [0.92, 2.47] 
 
 
2.64 [1.31, 5.30] 
Extended Better    Control Better 
 Clinical Impact of Extended DAPT after PCI 
   A metanalysis of Randomized trials (n=8231) 
 N Engl J Med 2010;362:1374–1382 
 Circulation 2012;125:2015–2026 
 Circulation 2012;125:505–513. 
 J Am Coll Cardiol. 2012 Oct 9;60(15):1340-8. 
Cassese et al Eur Heart Journal 2012; 33: 3078-3087 
DAPT post stent implantation  
Stent thrombosis – new generation of stents 
Drug eluted stents 1st vs 2nd generation 
Giustino G, et al. J Am Coll Cardiol 2015;65:1298–310 
Patient oriented strategy 












Morte EAM Revasc. AVCAll death AMI sc Stroke 
João Morais, 2016 to be published 
Single centre 
N=965 
12 months f-up 




   4,5%  2,9%  7,7%  2,1% 








Time in Years 
0 1 2 3 
All  
Culprit lesion (CL) related 








Number at risk 
ALL 697                                      557  506             480 
CL related 697                                      590 543            518 
NCL related 697                                      595 553             521 






















HR (95% CI) ≤ 1 Year: 
0.99 (0.84, 1.16) 
HR (95% CI) > 1 Year: 
0.72 (0.54, 0.97) 
Primary Efficacy Endpoint to 30 Months 
(Age < 75 years) 
HR (95% CI): 
0.91 (0.79, 1.05) 
P = 0.21 
Interaction P = 0.07 
Prasugrel vs. Clopidogrel for Acute 
Coronary Syndromes Patients Managed 
without Revascularization 
the TRILOGY ACS trial 
Background – 1° Efficacy  Evaluation 
Overall Population 
CV Death, MI, or Stroke  
9.3% 
10.5% 
Hazard Ratio 0.87 
p < 0.001 
N = 26449 
Mean f/u: 2.5 years Placebo 
Vorapaxar 
GUSTO Mod/Sev at 3 yrs 
  4.2 v. 2.5%, HR 1.66, p<0.001 


























Extended DAPT                        Udell’s meta-analysis 









Final remarks - I 
Appropriate patient selection is the key to handle the 
delicate balance between preventing thrombosis and 
provoking bleeding  
Patients with an established history of ACS and / or 
stent implantation may benefit of DAPT 
prolongation. The exact time duration is unknown 
Patient oriented approach should be preferred over a 
more simplistic way focusing only on the stent 
Final remarks - II 
Individual characteristics 
Thrombotic risk  
Bleeding risk 
Associated co-factors  
DAPT score 
Stent characteristics 
Type of stent  
(nr, length, location, diameter, overlap, dissection)  
Coronary anatomy 
Individualized therapy should be based on 
Many thanks 
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